Genmab loses appeal in Darzalex royalties arbitration case against Johnson & Johnson
Fierce Pharma
JANUARY 23, 2024
While sales for Johnson & Johnson’s Darzalex continue to boom—as the company reported in its quarterly earnings presentation on Tuesday—the pharma major got more good news about its blockbuster | An appeal arbitrator has rejected Genmab’s claim that it is due additional milestone and royalty payments from Johnson & Johnson for Darzalex. The Danish biotech was hoping to overturn a 2-1 ruling in a second arbitration between the companies over Darzalex royalties.
Let's personalize your content